ITM Isotopen Technologien München

ITM is a leading radiopharmaceutical biotech company focused on precision oncology, with a core strength in the manufacturing of high-purity, non-carrier-added (n.c.a.) radioisotopes like Lutetium-177. The company is advancing a deep and broad clinical pipeline of targeted radioligand therapies (RLTs) and diagnostics, with its lead candidate, n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11), in Phase 3 for neuroendocrine tumors. ITM operates an integrated model from isotope production to finished drug, positioning it as a key player in the rapidly evolving targeted radiotherapy market.

Integrated platform for high-purity, non-carrier-added (n.c.a.) radioisotope production (e.g., Lutetium-177), radiochemistry, and targeted radioligand therapy development.

ITM competes in a rapidly consolidating field dominated by Novartis (with approved drugs Pluvicto and Lutathera) and other large players like Bayer and AstraZeneca. Its primary competitive advantages are its proprietary n.c.a. Lu-177 production, which may offer a therapeutic benefit, and its broad, integrated pipeline. Competition is fierce for targets like PSMA and somatostatin receptors.